HomeCommentary

Commentary

Policymakers Face Balancing Act over Opdivo Re-Pricing
(Oct.17.2016)

The die has been cast - Opdivo (nivolumab) will be re-priced before the next FY2018 drug price revision. Now the question is how much lower? When? And, how will it affect the price-setting of its archrival Keytruda (pembrolizumab)? ...

(LOG IN FOR FULL STORY)

News Calendar